This article is more than 5 years old. Information may no longer be current.

VIDEO: Cemiplimab ‘a new standard’ for metastatic cutaneous squamous cell carcinoma

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

CHICAGO — Cemiplimab demonstrated considerable antitumor activity among patients with metastatic cutaneous squamous cell carcinoma, according to results of the EMPOWER-CSCC-1 trial presented at ASCO Annual Meeting.

Researchers concluded the trial results strongly support the recent FDA approval of cemiplimab (Libtayo; Regeneron, Sanofi Genzyme), a human monoclonal antibody that targets PD-1.

Alexander Guminski, MD, a medical oncologist from Sydney, Australia, and one of the investigators on the trial, spoke with HemOnc Today about the trial results and their potential clinical implications.

“This trial establishes a new standard for the treatment of patients with metastatic cutaneous squamous cell carcinoma, which is an important and often underrepresented and underrecognized disease,” Guminski told HemOnc Today. – by Mark Leiser

Reference: Guminski AD, et al. Abstract 9526. Presented at: ASCO Annual Meeting; May 31-June 4, 2019; Chicago.

Disclosure: Guminski reports advisory board roles with Merck KGaA, Pfizer, Regeneron, Sanofi and Sun Pharma.